Thank you for the question.
Definitely access to drugs is a huge issue, so I tend to support TB projects in resource-limited settings, such as southern Africa, and as was mentioned, India and Ukraine. Often health care providers know that a strong treatment regimen involving four or five or six drugs is necessary, but the problem is that they might have access to only two of these drugs. So they end up giving two drugs, which is an inadequately robust regimen, and what they're actually doing is making the problem worse. This is something we need to correct.
There are three ways to treat TB. You can give the proper treatment, you can give no treatment, or you can give the incorrect treatment. Giving no treatment is better than giving a weak treatment. Unfortunately, as it stands now, I would say the majority of people with drug-resistant TB around the world receive incorrect treatment, either because they're not diagnosed on time or because those drugs just aren't available.